Firebrick Pharma Health Care
Biotech Healthcare Pharmaceuticals

$0.155 0.005 (3.33%)

High $0.16	Low $0.15	Trades 7	Turnover $4,468	Volume 29,243
30 June 2023 at 3:01pm

Market Cap (23-Jul) $7,700,372 (0th)	Close (30-Jun) $0.155 0 (0%)	Volume (30-Jun) 29,243	Shortsold (1-Jul) 19,206 (0.01%) (619th)
52w High $0.085	52w Low $0.027	P/E -	EPS -0.01

Short Interest

ASIC data, 1 Jul 2026

% Shorted

0.01%

vs 0.01% prior report

Most Shorted Rank

619th

of 709 shorted ASX stocks

Peak Short

0.01%

Jan 2025

Days to Cover

0.1

at 50d avg vol

View full short position history →

	Subject
	FRE FRE Ann: Cleansing Notice
	1 (current) 2 3
	FRE FRE Ann: Application for quotation of securities - FRE
	FRE FRE Ann: June 2022 Quarterly Activity Report & Appendix 4C
	FRE FRE Ann: Firebrick Presents at Euroz Hartleys Healthcare Conference
	FRE FRE Ann: Outcome of s60 appeal for Nasodine and next steps
	FRE FRE Ann: Trading Halt
	FRE FRE Ann: Notification of cessation of securities - FRE
	FRE FRE Ann: Initial Director's Interest Notice - Richard Treagus
	FRE FRE Ann: Proposed issue of securities - FRE
	FRE FRE Ann: Nasodine Patent Granted in Malaysia
	FRE FRE Ann: Firebrick Appoints Dr Richard Treagus as Director
	FRE FRE Ann: Firebrick starts Phase 3 common cold trial of Nasodine
	FRE FRE Ann: March 2022 Quarterly Activity Report & Appendix 4C
	FRE FRE Ann: Firebrick starts COVID-19 trial of Nasodine
	FRE FRE Ann: Investor Presentation - Euroz Hartleys Rottnest Conference
	FRE FRE Ann: Investor Presentation - Euroz Hartleys Rottnest Conference
	FRE FRE Ann: FRE to file appeal seeking immediate approval of Nasodine
	FRE FRE Ann: Nasodine US Patent Granted for COVID-19
	FRE FRE Ann: 31 December Interim Financial Report & Appendix 4D
	FRE FRE Ann: Nasodine in vitro and pilot human COVID-19 studies published
	FRE FRE Ann: Nasodine COVID-19 trial receives SAHPRA approval
	FRE FRE Ann: Becoming a substantial holder - Stephen Goodall
	FRE FRE Ann: Becoming a substantial holder - Peter Molloy
	FRE FRE Ann: Becoming a substantial holder - Firebrick Pharma
	FRE FRE Ann: Initial Director's Interest Notice - Stephen Goodall
	FRE FRE Ann: Initial Director's Interest Notice - Peter Molloy
	FRE FRE Ann: Initial Director's Interest Notice - Phyllis Gardner
	FRE FRE Ann: Pre-Quotation Disclosure
	FRE FRE Ann: Top 20 Holders
	FRE FRE Ann: Distribution Schedule
	FRE FRE Ann: Securities Trading Policy
	FRE FRE Ann: Corporate Governance Statement
	FRE FRE Ann: Employee Incentive Plan
	FRE FRE Ann: Annual Report 30 June 2021
	FRE FRE Ann: Annual Report 30 June 2020
	FRE FRE Ann: Constitution
	FRE FRE Ann: Prospectus
	FRE FRE Ann: Information Form and Checklist
	FRE FRE Ann: Appendix 1A
	FRE FRE Ann: ASX Market Release - Admission and Quotation
	FRE FRE Article: Nasal spray business Firebrick Pharma caps off $7m IPO

End of Day Prices

Date	Close	Volume	Change
23-Jul	$0.03	59,878	0.00 (10.00%)
22-Jul	$0.03	0	0.00 (0.00%)
21-Jul	$0.03	73,698	0.00 (0.00%)
20-Jul	$0.03	87,766	+0.00 (7.14%)
17-Jul	$0.03	364,366	-0.04 (56.92%)
18-Sep	$0.07	86,441	0.00 (4.41%)
12-Sep	$0.07	9,012	+0.00 (4.62%)
11-Sep	$0.07	74,462	-0.01 (8.45%)
05-Sep	$0.07	135,388	0.00 (0.00%)
04-Sep	$0.07	157	0.00 (0.00%)
03-Sep	$0.07	13,158	0.00 (5.33%)
29-Aug	$0.08	0	0.00 (0.00%)
28-Aug	$0.08	0	0.00 (0.00%)
22-Aug	$0.08	174,657	0.00 (0.00%)
21-Aug	$0.08	317,245	-0.01 (6.25%)
2 up, 6 down, and 7 flat days

Firebrick Pharma Health Care
Biotech Healthcare Pharmaceuticals

Short Interest

Followers

Prices

Announcements

End of Day Prices

FRE Firebrick Pharma Health Care Biotech Healthcare Pharmaceuticals

Short Interest

Followers

Prices

Announcements

End of Day Prices

Firebrick Pharma Health Care
Biotech Healthcare Pharmaceuticals